Previous 10 | Next 10 |
DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today ann...
Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer Partnership designed to leverage artificial intelligence solutions to identify ...
Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th PR Newswire DALLAS , Sept. 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN) , a clinical stage biopharmaceutical company using its proprietary RADR ® ...
Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September PR Newswire DALLAS , Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® arti...
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives Harry Kochat, Ph.D. Appointed Senior Director of CMC and Manufacturing Quality Affairs Darlene Bunpian, MPH Appointed Lead Clinical Tr...
FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas ...
Gainers: Locust Walk Acquisition (NASDAQ:LWACU) +159%. Aditxt (NASDAQ:ADTX) +72%. Takung Art (NYSE:TKAT) +56%. Jiayin (NASDAQ:JFIN) +26%. Universal Security Instruments (NYSE:UUU) +23%. ScanSource (NASDAQ:SCSC) +18%. Lantern Pharma (NASDAQ:LTRN) +18%. InnSuites Hospitality Trust (NYSE:I...
Lantern is <$150m market cap biotech focused on AI-driven drug-discovery and development. This has proven to be an unpopular sector of biotech across the past 12 months, with a lack of tangible progress causing share prices of most companies to fall. Lantern has 2 clinical oppo...
Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration - LP-184 treatment induced tumor regression evidenced by over 106% tumor growth inhibition - LP-184 reduced xenograft tumor volume in mi...
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer PR Newswire DALLAS , Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinica...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...